ReviewArchives of toxicology2026
Mitochondrial lipid remodeling in sepsis-associated acute kidney injury: a cardiolipin-centered convergence framework.
Review in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mitochondrial immunometabolism in sepsis: bridging immune cell dysfunction and organ failure.Frontiers in immunology · 2026Review
- Growth Differentiation Factor 15 (GDF15) Protects Against Sepsis-Associated Acute Kidney Injury via Suppression of TLR4-MyD88-NF-κB Signaling and Ferroptosis.BioFactors (Oxford, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sepsis-associated acute kidney injury (S-AKI) is a frequent and severe complication of sepsis in which metabolic dysfunction and inflammatory activation develop in parallel and reinforce each other. Although mitochondrial dysfunction is widely recognized in S-AKI, the structural mechanisms linking mitochondrial bioenergetic failure to innate immune signaling remain incompletely understood. Emerging evidence suggests that mitochondrial lipid remodeling-particularly alterations in cardiolipin (CL)-may represent a structural interface connecting these processes. As a signature phospholipid of the inner mitochondrial membrane, cardiolipin supports cristae architecture, stabilizes respiratory chain supercomplexes, and maintains efficient oxidative phosphorylation. In renal tubular epithelial cells, which depend heavily on mitochondrial oxidative metabolism, disruption of cardiolipin homeostasis may have particularly profound consequences. Under septic stress, oxidative injury and dysregulated lipid remodeling alter cardiolipin composition and distribution, contributing to respiratory chain instability, impaired ATP production, and increased reactive oxygen species generation. In parallel, cardiolipin oxidation or externalization can transform mitochondrial membranes into signaling platforms that promote inflammasome activation and mitochondrial danger-associated molecular patterns (mtDAMPs) release. In this review, we propose a cardiolipin-centered framework that integrates mitochondrial bioenergetic failure with inflammatory amplification in S-AKI. By positioning mitochondrial lipid remodeling at the intersection of metabolism and innate immunity, this framework highlights mitochondrial lipid homeostasis as a potential mechanistic node and therapeutic entry point in septic kidney injury.
Indexed as
Identifiers
42084613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.